- Home
- DMA vs INMB Comparison
DMA vs INMB Comparison
Compare DMA & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- INMB
- Stock Information
- Founded
- DMA 2011
- INMB 2015
- Country
- DMA United States
- INMB United States
- Employees
- DMA N/A
- INMB N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- DMA Finance
- INMB Health Care
- Exchange
- DMA Nasdaq
- INMB Nasdaq
- Market Cap
- DMA 78.3M
- INMB 68.9M
- IPO Year
- DMA N/A
- INMB 2019
- Fundamental
- Price
- DMA $8.63
- INMB $2.53
- Analyst Decision
- DMA
- INMB Buy
- Analyst Count
- DMA 0
- INMB 4
- Target Price
- DMA N/A
- INMB $9.53
- AVG Volume (30 Days)
- DMA 34.6K
- INMB 2.9M
- Earning Date
- DMA 01-01-0001
- INMB 08-07-2025
- Dividend Yield
- DMA 2.04%
- INMB N/A
- EPS Growth
- DMA N/A
- INMB N/A
- EPS
- DMA N/A
- INMB N/A
- Revenue
- DMA N/A
- INMB $50,000.00
- Revenue This Year
- DMA N/A
- INMB $212.27
- Revenue Next Year
- DMA N/A
- INMB $10,184.28
- P/E Ratio
- DMA N/A
- INMB N/A
- Revenue Growth
- DMA N/A
- INMB N/A
- 52 Week Low
- DMA $4.78
- INMB $1.89
- 52 Week High
- DMA $8.00
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- DMA 44.80
- INMB 41.61
- Support Level
- DMA $8.72
- INMB $2.42
- Resistance Level
- DMA $8.89
- INMB $2.61
- Average True Range (ATR)
- DMA 0.08
- INMB 0.22
- MACD
- DMA -0.01
- INMB 0.09
- Stochastic Oscillator
- DMA 15.63
- INMB 26.67
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.